Biotechnology venture capital funding continued a multi-year surge in the first half of 2026, as strong public market performance and a spike in dealmaking activity helped spur interest in privately held drug startups, BioPharma Dive data show.
Data compiled by BioPharma Dive indicate that at least 68 biotech companies banked more than $9.1 billion in venture capital funding between January and June. The total amount raised represents the highest first-half sum since the start of 2022, among companies backed by the 26 firms BioPharma Dive tracks.
Venture capital has “continued to go strong” despite the threat of a U.S. government crackdown on investments in Chinese drug assets and turmoil at the Food and Drug Administration, said Ben Zercher, a senior analyst at research firm Pitchbook. And most investments come in the form of “megarounds” worth $100 million or more. About 76% of the total funds raised in the first half were part of those larger financings, according to BioPharma Dive data.
Gwendolyn Wu/BioPharma Dive, data from BioPharma Dive
Partly driving that momentum, some experts say, is the encouraging performance of initial public offerings. So far in 2026, 13 firms have brought in a combined $4.5 billion in IPO proceeds. Their median haul of almost $302 million is unusually large compared to prior years, and two companies, Parabilis Medicines and Kailera Therapeutics, broke sector records.
